
Graft-vs-Host Disease (GVHD)
Latest News

Advertisement
Latest Videos
CME Content
Advertisement
More News

Two existing, well-validated patient-reported outcome (PRO) measures may be useful as a prognostic marker for mortality and assist with treatment selection for patients with cutaneous chronic graft-vs-host disease (GVHD).


After years of dependence on systemic corticosteroids, ruxolitinib treatment was effective for an adolescent patient with graft-versus-host disease (GVHD) who was initially thought to have eosinophilic gastroenteritis.
Advertisement
Advertisement
Trending on AJMC
1
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
2
Value-Based Care Interventions and Management of CKD Progression
3
Defining the Role of Rilzabrutinib in ITP Management
4
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
5